DHCR7-DT and chronic myelogenous leukemia, BCR-ABL1 positive: After determination of RP2D, two pivotal studies were initiated at 10 sites in China from April 26, 2019, to October 8, 2019, that enrolled 41 patients with T315I-mutated CML-CP and 23 with T315I-mutated CML-AP.